首页> 外文OA文献 >Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

【2h】

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

机译：内分泌治疗患有2年Tamoxifen与2年的绝经乳腺患者高风险早期乳腺癌和持续循环肿瘤细胞的患者 - 第一个成功的肝内分泌治疗子研究结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Fabienne Schochter; Brigitte Rack; Marie Tzschaschel; Arkadius Polasik; Ulrich Andergassen; Elisabeth Trapp; Marianna Alunni-Fabbroni; Andreas Schneeweiss; Volkmar Müller; Klaus Pantel; Jörg Gade; Ralf Lorenz; Mahdi Rezai; Hans Tesch; Ulrike Soeling; Tanja Fehm; Sven Mahner; Christian Schindlbeck; Werner Lichtenegger; Matthias W. Beckmann; Peter A. Fasching; Wolfgang Janni; Thomas W.P. Friedl;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study [J] . Oncology research and treatment. . 2018,第3期

机译：内分泌治疗患有2年Tamoxifen与2年的绝经后期患者高危早期乳腺癌患者和持续循环肿瘤细胞 - 第一个成功的肝内分泌治疗子研究结果
2. Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial [J] . Ohashi Yasuo, Shiba Eiichi, Yamashita Hiroko, Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer . 2018,第3期

机译：2年和3岁尿液蛋白醋酸蛋白的生命质量比较，每3个月储存与Tamoxifen在先生响应乳腺癌患者中的佐剂内分泌治疗组合：随机对照试验
3. A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5?years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer [J] . Junichi Kurebayashi, Eiichi Shiba, Tatsuya Toyama, Breast cancer . 2021,第3期

机译：随机对照研究评估Leuprorelin醋酸甘油蛋白的安全性和功效2与三个月为3或更多年的疗效，以5〜3或更多年在预氧化患者中辅助治疗患者的内分泌反应乳腺癌
4. Nanosecond, low voltage electro-endocrine-therapy for breast cancer treatment [C] . Funian Xiao, Leary J.F., Reece L., 2010 Annual Report Conference on Electrical Insulation and Dielectric Phenomena . 2010

机译：纳秒级低压电内分泌疗法，用于乳腺癌治疗
5. A time to question: A study of the information needs of postmenopausal breast cancer patients regarding endocrine therapy. [D] . TeBrake, Melissa Lynn. 2010

机译：问题时间：对绝经后乳腺癌患者有关内分泌治疗的信息需求的研究。
6. Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial [O] . Yasuo Ohashi, Eiichi Shiba, Hiroko Yamashita, -1

机译：绝经前内分泌反应性乳腺癌患者每隔3个月每2个月和3年或更长时间服用醋酸亮丙瑞林联合他莫昔芬辅助内分泌治疗的生活质量比较：一项随机对照试验
7. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer [O] . Eiichi Shiba, Hiroko Yamashita, Junichi Kurebayashi, 2015

机译：一项随机对照研究，评估绝经前内分泌敏感型乳腺癌患者每隔3个月每3个月醋酸醋酸亮丙瑞林储库2年，3年或3年以上与他莫昔芬5年作为辅助治疗的安全性和有效性

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

著录项

相似文献

相关主题

期刊订阅